{"id":"https://openalex.org/W2016663561","doi":"https://doi.org/10.1158/0008-5472.can-07-6404","title":"A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model","display_name":"A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model","alternate_titles":[],"publication_year":2008,"publication_date":"2008-07-15","ids":{"openalex":"https://openalex.org/W2016663561","doi":"https://doi.org/10.1158/0008-5472.can-07-6404","mag":"2016663561","pmid":"https://pubmed.ncbi.nlm.nih.gov/18632601"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.can-07-6404","doi":"https://doi.org/10.1158/0008-5472.can-07-6404","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-07-6404","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2016663561"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003658156","display_name":"Eline Menu","orcid":"https://orcid.org/0000-0002-0805-6581","observed_orcids":["https://orcid.org/0000-0002-0805-6581"]},"institutions":[{"id":"https://openalex.org/I13469542","display_name":"Vrije Universiteit Brussel","ror":"https://ror.org/006e5kg04","country_code":"BE","type":"education","lineage":["https://openalex.org/I13469542"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eline Menu","raw_affiliation_strings":["3Vrije Universiteit Brussels, Laarbeeklaan 103, Brussels, Belgium; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Vrije Universiteit Brussels, Laarbeeklaan 103, Brussels, Belgium; and","institution_ids":["https://openalex.org/I13469542"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012968070","display_name":"Josefina Garc\u00eda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Josefina Garcia","raw_affiliation_strings":["1Department of Pathology and","Weill Cornell Medicine New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pathology and","institution_ids":[]},{"raw_affiliation_string":"Weill Cornell Medicine New York","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080145536","display_name":"Xiangao Huang","orcid":"https://orcid.org/0009-0005-1919-4831","observed_orcids":["https://orcid.org/0009-0005-1919-4831"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiangao Huang","raw_affiliation_strings":["1Department of Pathology and","Weill Cornell Medicine New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pathology and","institution_ids":[]},{"raw_affiliation_string":"Weill Cornell Medicine New York","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111662141","display_name":"Maurizio Di Liberto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maurizio Di Liberto","raw_affiliation_strings":["1Department of Pathology and","Weill Cornell Medicine New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pathology and","institution_ids":[]},{"raw_affiliation_string":"Weill Cornell Medicine New York","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076199303","display_name":"Peter L. Toogood","orcid":"https://orcid.org/0000-0002-8938-6960","observed_orcids":["https://orcid.org/0000-0002-8938-6960"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter L. Toogood","raw_affiliation_strings":["4Pfizer Global Research and Development, Ann Arbor, Michigan, and San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Pfizer Global Research and Development, Ann Arbor, Michigan, and San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063926652","display_name":"Isan Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Isan Chen","raw_affiliation_strings":["4Pfizer Global Research and Development, Ann Arbor, Michigan, and San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Pfizer Global Research and Development, Ann Arbor, Michigan, and San Diego, California","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014026887","display_name":"Karin Vanderkerken","orcid":"https://orcid.org/0000-0002-2137-7179","observed_orcids":["https://orcid.org/0000-0002-2137-7179"]},"institutions":[{"id":"https://openalex.org/I13469542","display_name":"Vrije Universiteit Brussel","ror":"https://ror.org/006e5kg04","country_code":"BE","type":"education","lineage":["https://openalex.org/I13469542"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karin Vanderkerken","raw_affiliation_strings":["3Vrije Universiteit Brussels, Laarbeeklaan 103, Brussels, Belgium; and","Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Vrije Universiteit Brussels, Laarbeeklaan 103, Brussels, Belgium; and","institution_ids":["https://openalex.org/I13469542"]},{"raw_affiliation_string":"Hematology","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000554189","display_name":"Selina Chen\u2010Kiang","orcid":"https://orcid.org/0000-0002-8549-6177","observed_orcids":["https://orcid.org/0000-0002-8549-6177"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Selina Chen-Kiang","raw_affiliation_strings":["1Department of Pathology and","2Graduate Program in Immunology and Microbial Pathogenesis, Weill Medical College of Cornell University, New York, New York;","PfIzer Global Research and Development"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pathology and","institution_ids":[]},{"raw_affiliation_string":"2Graduate Program in Immunology and Microbial Pathogenesis, Weill Medical College of Cornell University, New York, New York;","institution_ids":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]},{"raw_affiliation_string":"PfIzer Global Research and Development","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.3901,"has_fulltext":false,"cited_by_count":115,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.94658977,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"68","issue":"14","first_page":"5519","last_page":"5523"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.949999988079071},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9509999752044678},{"id":"https://openalex.org/keywords/cdk4-6-inhibition","display_name":"CDK4/6 inhibition","score":0.800000011920929},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7639999985694885},{"id":"https://openalex.org/keywords/g1-cell-cycle-arrest","display_name":"G1 cell cycle arrest","score":0.9380000233650208},{"id":"https://openalex.org/keywords/cyclin-d2","display_name":"cyclin D2","score":0.875},{"id":"https://openalex.org/keywords/p27","display_name":"p27","score":0.9639999866485596},{"id":"https://openalex.org/keywords/rb-phosphorylation","display_name":"retinoblastoma protein phosphorylation","score":0.8370000123977661}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8202358484268188},{"id":"https://openalex.org/C199649820","wikidata":"https://www.wikidata.org/wiki/Q14911762","display_name":"Cyclin-dependent kinase 6","level":5,"score":0.697387158870697},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6623293161392212},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6545459032058716},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.5744614601135254},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.4930376708507538},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.46173131465911865},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4289499521255493},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.41285794973373413},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39494138956069946},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36701059341430664},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.35516422986984253},{"id":"https://openalex.org/C120089663","wikidata":"https://www.wikidata.org/wiki/Q59250999","display_name":"Cyclin","level":4,"score":0.2841770052909851},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24123793840408325},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.11918476223945618},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.0},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008810","descriptor_name":"Mice, Inbred C57BL","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009368","descriptor_name":"Neoplasm Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D050760","descriptor_name":"Cyclin-Dependent Kinase Inhibitor p27","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051358","descriptor_name":"Cyclin-Dependent Kinase 4","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051361","descriptor_name":"Cyclin-Dependent Kinase 6","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1158/0008-5472.can-07-6404","doi":"https://doi.org/10.1158/0008-5472.can-07-6404","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-07-6404","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmid:18632601","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18632601","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"},{"id":"pmh:oai:vubissmart:VUBISSMART:2000:44695","doi":null,"is_oa":false,"landing_page_url":"https://biblio.vub.ac.be/vubir/a-novel-therapeutic-combination-using-pd-0332991-and-bortezomib-study-in-the-5t33mm-myeloma-model(8b126cbc-b2bf-4679-85aa-ce57ab516deb).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306402573","display_name":"VUBIR (Vrije Universiteit Brussel)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I13469542","host_organization_name":"Vrije Universiteit Brussel","host_organization_lineage":["https://openalex.org/I13469542"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.319.1450","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.319.1450","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://cancerres.aacrjournals.org/content/68/14/5519.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G6219536670","display_name":null,"funder_award_id":"R0I CA 120531","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1975203568","https://openalex.org/W1979950447","https://openalex.org/W1980268334","https://openalex.org/W1985679278","https://openalex.org/W2033156691","https://openalex.org/W2038018463","https://openalex.org/W2056907919","https://openalex.org/W2057274133","https://openalex.org/W2060871248","https://openalex.org/W2069808019","https://openalex.org/W2071959000","https://openalex.org/W2083561654","https://openalex.org/W2121619780","https://openalex.org/W2125211913","https://openalex.org/W2139230560","https://openalex.org/W2148654292","https://openalex.org/W2153985422","https://openalex.org/W2154626333","https://openalex.org/W2170331239","https://openalex.org/W2584400607"],"related_works":["https://openalex.org/W2580760784","https://openalex.org/W2275272360","https://openalex.org/W2559951930","https://openalex.org/W2125211913","https://openalex.org/W2584400607","https://openalex.org/W2593242170","https://openalex.org/W2980186751","https://openalex.org/W2569412161","https://openalex.org/W2582578468","https://openalex.org/W2981063766"],"abstract_inverted_index":{"Multiple":[0],"myeloma":[1,56,70,90,96,198],"(MM)":[2],"remains":[3],"incurable":[4],"partly":[5],"because":[6],"no":[7],"effective":[8],"cell":[9,19,50,134,146,222],"cycle-based":[10,223],"therapy":[11],"has":[12,43],"been":[13,44],"available":[14],"to":[15,46,109,164,185,205],"both":[16],"control":[17],"tumor":[18,60,74,102,165,183,199,203],"proliferation":[20],"and":[21,36,40,58,117,127,145,159,167,201,220],"synergize":[22],"with":[23,79],"cytotoxic":[24,80],"killing.":[25],"PD":[26,77,137,179,193],"0332991":[27,78,138,180],"is":[28],"an":[29,212],"orally":[30],"active":[31],"small":[32],"molecule":[33],"that":[34,100],"potently":[35,139],"specifically":[37],"inhibits":[38,140],"Cdk4":[39],"Cdk6.":[41],"It":[42],"shown":[45],"induce":[47],"rapid":[48],"G(1)":[49,150,176],"cycle":[51,147],"arrest":[52,177],"in":[53,62,89,92,106,151,157,171,208],"primary":[54,154],"human":[55],"cells":[57,103,184,204],"suppress":[59],"growth":[61],"xenograft":[63],"models.":[64],"To":[65],"improve":[66],"therapeutic":[67],"targeting":[68],"of":[69,111,115,123,130,143,175,190,211],"progression,":[71],"we":[72],"combined":[73],"suppression":[75,166],"by":[76,82,125,178,187,192],"killing":[81,186,207],"bortezomib,":[83],"a":[84,131,168,218],"proteasome":[85],"inhibitor":[86],"widely":[87],"used":[88],"treatment,":[91],"the":[93,128,209],"immunocompetent":[94],"5T33MM":[95,101,155,182],"model.":[97],"We":[98],"show":[99],"proliferate":[104],"aggressively":[105,152],"vivo":[107,158],"due":[108],"expression":[110],"cyclin":[112],"D2,":[113],"elevation":[114],"Cdk4,":[116],"impaired":[118],"p27(Kip1)":[119],"expression,":[120],"despite":[121],"inhibition":[122],"Cdk4/6":[124,191],"p18(INK4c)":[126],"maintenance":[129],"normal":[132],"plasma":[133],"transcription":[135],"program.":[136],"Cdk4/6-specific":[141],"phosphorylation":[142],"Rb":[144],"progression":[148],"through":[149],"proliferating":[153],"cells,":[156],"ex":[160],"vivo.":[161],"This":[162],"leads":[163],"significant":[169],"improvement":[170],"survival.":[172],"Moreover,":[173],"induction":[174],"sensitizes":[181,202],"bortezomib.":[188],"Inhibition":[189],"0332991,":[194],"therefore,":[195],"effectively":[196],"controls":[197],"expansion":[200],"bortezomib":[206],"presence":[210],"intact":[213],"immune":[214],"system,":[215],"thereby":[216],"representing":[217],"novel":[219],"promising":[221],"combination":[224],"therapy.":[225]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2016663561","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":14}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
